Top
Amyotrophic lateral sclerosis - Healing Genes
597
post-template-default,single,single-post,postid-597,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Amyotrophic lateral sclerosis

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

A Phase II Study of Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis


Phase 2

DESCRIPTION:

Mayo Clinic researchers in Rochester, MN, seek ALS patients to participate in a trial exploring the safety and efficacy of a treatment involving the patient’s own (autologous)  stem cells. The treatment will draw stem cells from the patient’s body fat and be multiplied in a lab before being injected into the patient’s spinal fluid through an intrathecal (spinal) injection.

The trial requires treatment every 3 months for a total of 4 intrathecal injections over 12 months.


PATIENT MUST:

  • Be 18 years of age or older
  • Have a diagnosis of ALS
  • Must agree to 2 forms of birth control, if female
  • Not have an autoimmune disorder, malignancy 5 years prior, or prior stem cell therapy of any kind

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Mesenchymal stem cells will be drawn from the patient’s adipose, or fat, tissue.
  3. After the stem cells are amplified in the lab (over a period of weeks), the patient will return to receive a single dose of the stem cells via spinal injection 3 months for a total of 4 intrathecal injections over 12 months.

LOCATIONS AND CONTACTS:

The study site is at Mayo Clinic in Rochester, MN. Map.

Contacts:

Michelle M Turner | [email protected] | 507-284-2676

Carol Denny | [email protected] | 507-284-2676

 

SPONSOR INFORMATION:

Mayo Clinic & State of Minnesota Regenerative Medicine

 

Or go online:

https://www.mayo.edu/research/clinical-trials/cls-20349345

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader